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Abstract The m.3243A > G mutation has become known as
the MELAS mutation. However, many other clinical pheno-
types associated with this mutation have been described, most
frequently being maternally inherited diabetes and deafness
(MIDD). The m.3243A > G mutation, can be detected in
virtually all tissues, however heteroplasmy differs between
samples. Recent reports indicate, a preference to perform
mutation analysis in urinary epithelial cells (UEC). To test
this, and to study a correlation between the mutational load in
different tissues with two mitochondrial scoring systems
(NMDAS and NPMDS) we investigated 34 families carrying
the m.3243A > G mutation. Heteroplasmy was determined in
three non-invasively collected samples, namely leucocytes,
UEC and buccal mucosa. We included 127 patients, of which
82 carried the m.3243A > G mutation. None of the children
(n011) had specific complaints. In adults (n071), a median
NMDAS score of 15 (IQR 10-24) was found. The most
prevalent symptoms were hearing loss(48%), gastro-intestinal
problems(42%), exercise intolerance(38%) and glucose intol-
erance(37%). Ten patients had neurologic involvement. Buccal
mucosa had the best correlation with the NMDAS in all adults
(r00.437,p<0.001), whereas UEC had the strongest correla-
tion with the NMDAS in severely affected patients (r00.593,
p00.002). Heteroplasmy declined significantly with increasing
age in all three samples (leucocytes r0-0.705 (p<0.001), UEC
r0-0.374(p00.001), buccal mucosa r0-0.460(p<0.001). In
our cohort of 82 patients, the m.3243A > G mutation causes
a wide variety of signs and symptoms, MIDD being far more
prevalent than MELAS. Looking at the characteristics of the
three non-invasively available tissues for testing heteroplasmy





UEC Urinary epithelial cells
MELAS Mitochondrial myopathy encephalopathy,
lactate acidosis and stroke-like episodes
MIDD Maternally inherited diabetes and deafness
NMDAS Newcastle Mitochondrial Disease Adult Scale
NPMDS Newcastle Pediatric Mitochondrial Disease
Scale
FSGS Focal segmental glomerulosclerosis
LVH Left ventricular hypertrophy
MERRF Myoclonic epilepsy with ragged-red fibers
dNTP’s Deoxynucleotide triphosphates
PPi Pyrophosphate
QoL Quality of life
QoLP Quality of physical health
QoLM Quality of mental health
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Introduction
Mitochondria are responsible for production of adenosine
triphosphate (ATP), through oxidative phosphorylation
(OXPHOS). Mitochondrial dysfunction can result from muta-
tions in either nuclear DNA (nDNA) or mitochondrial DNA
(mtDNA).
The incidence of congenital mitochondrial disorders
based on an OXPHOS defect is at least 1:8500 of all live
births (Chinnery and Turnbull 2001).
Mitochondrial DNA encodes 37 genes, 22 code for
tRNA’s, two for rRNA’s and 13 code for subunits of the
OXPHOS complexes I, III, IV and V.
Two important features of mitochondrial mutations are;
A) maternal inheritance, it can be assumed that all relatives
from the maternal line are (dormant) carriers of the muta-
tion. This applies only if there is not a de novo mutation, and
B) heteroplasmy, human cells contain over 100 – 1000
mitochondria each, every mitochondrion contains 1-10 cop-
ies of mtDNA. When all mtDNA copies are mutated, there
is a homoplasmic mutation. When however not all mtDNA
copies are mutated, there is a variation in mutation load and
the mutation is called heteroplasmic (Cree et al. 2009).
Heteroplasmy can vary between different tissues of one
patient and between one tissue in one patient in time.
(Frederiksen et al. 2006) This variation in heteroplasmy
between tissues complicates the demonstration of a relation-
ship between the severity of the disease in a non accessible
organ (e.g., the heart or the brain) and the degree of hetero-
plasmy in blood, urine or buccal mucosa.
The acronymMELASwas first used in 1984 by Pavlakis et
al to describe a group of patients with Mitochondrial myopa-
thy, Encephalopathy, Lactic Acidosis and Stroke-like episodes
(Pavlakis et al. 1984). In 1990 the adenine to guanine transi-
tion at position 3243 ofmitochondrial DNA (m.3243A>G) in
the MT-TL1 gene encoding tRNALEU(UUR) was found as mo-
lecular basis for this disease (Goto et al. 1990; Kobayashi et al.
1990). A mutation in tRNA commonly causes a combined
defect of the mtDNA encoded OXPHOS complexes.
tRNALEU(UUR) is partially (∼12%) responsible for the incor-
poration of leucine into mitochondrial DNA encoded proteins,
tRNALEU(CUN) is responsible for the other part (∼88%)
(Wittenhagen and Kelley 2003). It is proposed that because of
the minimal role of tRNALEU(UUR) in incorporation of leucine,
a mutation in the tRNALEU(UUR) is less lethal and therefore
more frequently detected (Wittenhagen and Kelley 2003). The
m.3243A > G mutation in the MT-TL1 gene is the most
common cause of MELAS syndrome, therefore the mutation
is also known as the MELAS mutation. Later, more and more
phenotypic expressions of the m.3243A > G mutation were
found, including maternally inherited diabetes deafness
(MIDD)(van den Ouweland et al. 1992), hypertrophic cardio-
myopathy(Lev et al. 2004), macular dystrophy(Michaelides et
al. 2008), focal segmental glomeruloslerosis (FSGS) (Lowik
et al. 2005), myoclonic epilepsy with ragged-red fibers
(MERRF)(Durand-Dubief et al. 2004) and oligosymptomatic
variants of the acronym MELAS (Ma et al. 2010).
Epidemiologic studies show a m.3243A > G mutation preva-
lence of 7.59/100.000 in the population of North-East
England (Chinnery et al. 2000), 16.3/100.000 in the popula-
tion of Northern Finland (Majamaa et al. 1998) and up to 236/
100.000 in the population of Australia (Manwaring et al.
2007). These studies did not give a complete insight in the
phenotypic expression of the m.3243A > G mutation in the
subjects examined. The high mutation prevalence in the most
recent study indicates a high number of undiagnosed carriers of
the m.3243A > G mutation.
Since mitochondria and mtDNA are present in almost all
tissues, heteroplasmy can theoretically be assessed in virtually
every tissue. Two problems arise when testing heteroplasmy:
the convenience of obtaining the sample and the differences in
heteroplasmy levels between samples. For example, inva-
sively obtained muscle tissue heteroplasmy usually gives a
higher and more consistent level than conveniently attained
blood, in the last case possibly leading to false-negative
results. Recent studies showed a superiority of urine over
blood as preferred non-invasive tissue for mutation analysis
(Frederiksen et al. 2006; Ma et al. 2009; Marotta et al. 2009).
The relationship between mutation load and clinical pheno-
types has been a subject of research for many years (Chinnery
et al. 1997). Whittaker et al. (2009) and Ma et al. (2009)
recently showed a relationship between heteroplasmy levels
in urinary epithelia and clinical symptoms in a small number
of patients.
Some of the many questions regarding the m.3243A > G
mutation that we have include: Are all mutation carriers symp-
tomatic? Should these carriers undergo screening for frequent
and preventable symptoms such as cardiomyopathy, glucose
intolerance, nephropathy or macular dystrophy? How should
female carriers be counseled regarding fertility questions?
In this study, we clinically evaluated 34 Dutch families,
probands and maternal relatives, carrying the m.3243A > G
mutation. We provide data about the whole phenotypic
spectrum of m.3243A > G mutation as well as information
regarding the correlation between the level of heteroplasmy
in different samples and the clinical severity of the disease.
Patients and methods
Patients
All probands are patients of the Nijmegen Center for
Mitochondrial Disorders at the Radboud University
Nijmegen Medical Centre, The Netherlands, diagnosed with
the m.3243A >Gmutation in muscle or blood. All patients and
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maternal relatives were recruited by a letter, in which they were
invited to participate in this study. This study was approved by
the ethics committee of the Nijmegen-Arnhem region, The
Netherlands. Written informed consent according to the
Helsinki agreement was obtained from all parents and patients
≥12 years.
Newcastle mitochondrial disease scales
All patients were invited for a single visit to our out-patient
clinic. Adult patients (>18 yr) were scored using the Newcastle
Mitochondrial Disease Adult Scale (NMDAS)(Schaefer et al.
2006), pediatric patients (<18 yr) were scored using the
Newcastle Pediatric Mitochondrial Disease Scale (NPMDS)
(Phoenix et al. 2006). The NMDAS and NPMDS constitute a
validated method to monitor the clinical expression of mito-
chondrial disease and to follow-up the course of disease in
time. The NMDAS and NPMDS consist of the following four
sections. 1) Current function, gives insight into the general
functioning of patients in the past four weeks. 2) System-
specific involvement, uses a clinical history supplemented by
specific information to gain insight in the functioning of individ-
ual organ-systems. 3) Current clinical assessment, a general and
neurological clinical examination, gives insight in the current
functional status of the patient. This section includes three cog-
nition tests. We were able to use the English symbol test, since it
does not use language. For the reading test we used a Dutch
equivalent test. In absence of a Dutch equivalent test for the
Speed of Comprehension we could not use this test.We scored
the cognition based on the symbol test and reading test only.
Section 1 to 3 of the NMDAS consists respectively of ten,
nine and ten questions, which can be scored from 0 (no in-
volvement) to 5 (severe involvement). For section 4, Quality of
life, we used a Dutch translation of the SF-12v2 quality of life
test. A score from 0 to 70 for mental and physical health, where
50 is the population mean, is obtained from this quality of life
score. The NPMDS exist respectively of seven, ten and nine
questions, which can be scored from 0 (no involvement) to 3
(severe involvement). Section 4: Quality of life, uses a specially
designed quality of life questionnaire for children. These do not
have a reference score, so we can only use them to show a
difference in time, therefore they are not mentioned in this
report. Intra-observer and inter-observer variability was shown
to be low in both the NMDAS and the NPMDS (Phoenix et al.
2006; Schaefer et al. 2006). All patients were scored indepen-
dently by the same two investigators (PdL, SK), after which
consensus was reached. The consensus score is used in the
results of the study.
m.3243A > G mutation analysis
At the same visit during which the NMDAS or NPMDS was
scored, blood, saliva and urine was collected for heteroplasmy
analysis. DNAwas isolated from peripheral blood leukocytes
using a salting-out method. The urine sediments and buccal
swab samples were centrifuged for 10 min at 3000 r.p.m., the
pellet was washed with phosphate-buffered saline. DNAwas
extracted using a commercially available DNA isolation kit
(PuregeneTM DNA isolation kit; Gentra Systems, MN).
DNA samples were analyzed quantitatively using
PyrosequencingTM technology (Pyrosequencing, Upsala,
Sweden). Pyrosequencing was performed according to the
protocol of the manufacturer. PCR of a mtDNA fragment
containing the 3243 position was performed using the fol-
lowing primers: universal primer (biotinylated), 50-
GGGACACCGCTGATCGTTTA-30; forward primer, 50-
GACGGGACACCGCTGATCGTTTACAACTTAGTA
TTATACCCACAC-30; and reverse pr imer, 50-
ATTAGAATGGGTACAATGAGGA-30. PCR was carried
out in a 50 ml volume containing 0.02 mM forward primer,
0.2 mM reverse primer and 0.2 mM of the biotinylated
universal primer. PCR conditions were 92°C for 30 s, 55°
C for 30 s, 72°C for 30 s, for a total of 40 cycles. Single-
stranded template DNA, which in the present assay is the
forward strand of the fragment, was purified using
streptavidin-coated Sepharose beads. The actual pyrose-
quencing was performed on the PSQ96 platform using se-
quence primer 50-TATGCGATTACCGGGC-30. In a
pyrosequence reaction, the four different deoxynucleotide
triphosphates (dNTPs) are added separately one after the
other. The incorporation of dNTP is accompanied by release
of pyrophosphate (PPi). This PPi is involved in a light-
producing reaction of which the amount of light produced
is proportional to the number of nucleotides incorporated.
The light is detected by a charge coupled device camera and
seen as a peak in a pyrogram. Apyrase, a nucleotide-
degrading enzyme, continuously degrades ATP involved in
the light-producing reaction, and unincorporates dNTPs.
This switches off light production and regenerates the reaction
solution. Because the forward strand is used as template in the
sequencing reaction, the change detected in the present assay
concerns a T to C exchange. In fact, the amount of dTTP and
dCTP incorporated at position 3243 during the sequencing
reaction was determined in this way and from this the per-
centage of heteroplasmy was calculated. The pyrosequence
reaction of the m.3234A > G mutation has a precision of
1.5%. The mutation is detected from a heteroplasmy level
of 5%. The detection limit for the MELAS mutation
(m.3243A > G) was determined by serial dilution of a sample
containing this mutation with wild type mtDNA.
Statistics
We used descriptive statistics to present patient character-
istics and the results of the NMDAS and NPMDS. All data
are presented as a median with interquartile ranges (IQR,
J Inherit Metab Dis
25th and 75th percentiles). Non-parametric tests were used
if the data did not reflect a Gaussian distribution. Spearman’s
rho correlation coefficient was used to evaluate the relation-
ship between the clinical scores with the heteroplasmy in the
different tissues. Pearson’s correlation was used to correlate
heteroplasmy in different levels to each other and to age. A t-
test was used to compare the quality of life of the m.3243A >
G mutation carriers to reference values .
Results
Patient characteristics
Included in the study were 127 individuals from 34 families.
The cohort consists of 24 probands. Fourty-eight family
members were related in the first degree to a proband, 28
in the second degree, 18 in the third degree and nine in the
fourth degree. The age of the patients ranged from two
months to 80 years, median 39 years (IQR: 25 – 54 yr).
Forty-two patients were male and 85 female (ratio 1 : 2.02).
In 82 individuals the m.3243A > G mutation was detected in
at least one of the samples. In 45 family members the
mutation was not detected.
Children
Eleven children (4 male, 7 female) carrying the m.3243A >
G mutation were scored using the NPMDS. Two boys were
probands, the other nine patients were maternal family
members. The median age was 6 years (IQR 5.5-8.5 yrs).
Five children scored zero points on the NPMDAS, two
children scored one point, three children scored two points
and one child scored four points. The main complaints were
a delay in development (in five children) in early childhood,
which had been caught up by the time of investigation. One
girl attended special school for learning difficulties. One boy
had communicational problems both in his native language
(Turkish) and in Dutch. Heteroplasmy in UEC in these
children ranged from 8-93% and had a median level of
59% (IQR : 31.5 – 77%).
Adults
Seventy-one adult carriers (25 male, 46 female) of the
m.3243A > G mutation were scored using the NMDAS.
The median age was 45 years (IQR: 34-55 yr).
They had a median clinical score of: 4 (IQR: 1-7) on
section 1; 4 (IQR 1-8) on section 2; and 3 (IQR 0-6) on section
3. The total median score of section 1-3 was 15 (IQR 10-24).
Table 1 presents the symptoms sorted by prevalence. A
complete overview of all results can be found in Figs. 1a-c.
Summary of the most important findings
Hearing Fourty-eight carriers (67.6%) had hearing difficul-
ties, 24 carriers experienced mild deafness, whereas another
19 carriers had moderate deafness (not fully corrected with
hearing aid), three carriers had severe deafness (poor even
with hearing aid) and two carriers had end stage deafness
requiring a cochlear implant.
Exercise Tolerance: 38 carriers (53.5%) had a compro-
mised exercise tolerance. Twenty-five were only limited on
inclines or stairs, whereas the other carriers were also lim-
ited on flat services.
Gait stability and cerebellar ataxia: 36 carriers (50.7%)
reported difficulties maintaining their stability, 35 carriers
Table 1 Signs and
symptoms of the
m.3243A > G mutation
scored by the NMDAS,
sorted by prevalence
(n071)
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(49.3%) had difficulties with the heel-toe test at the clinical
assessment. Eight carriers reported difficulties on uneven
grounds and 21 carriers reported occasional balance prob-
lems when walking. Six carriers reported occasional falls
because of balance problems, one patient was unable to
walk unsupported. On clinical assessment 23 carriers had a
hesitant heel-toe test, nine were unable to maintain heel-toe
walking and three carriers were unable to walk heel-toe.
Gastro-intestinal symptoms Fourty-two carriers (59.2%)
reported gastro-intestinal symptoms. Fourteen had mild con-
stipation, six had occasional symptoms of irritable bowel.
Seventeen carriers had severe constipation (requiring daily
medication) or severe irritable bowel complaints, in five
carriers gastro-intestinal symptoms were that severe they
needed hospital admission, three of them underwent surgical
procedures for gastro-intestinal dysmotility.
Diabetes mellitus Thirty-seven carriers (52.1%) had a com-
promised glucose tolerance, for which ten were treated with
tablets (non insulin depending diabetes mellitus) and 20
required insulin treatment (insulin depending diabetes mel-
litus). Four patient were on a diet and two carriers received
no treatment for impaired glucose tolerance, one patient
reported diabetes gravidarum.
Ptosis Thirty-two carriers (45.1%) had a ptosis, mild ptosis
(not obscuring either pupil) occurred in 23 carriers, moderate
ptosis occurred in eight carriers, whereas one patient had a
severe ptosis (obscuring bilateral >1/3 of pupils).
Myopathy Thirty-four carriers (47.9%) had reduced muscle
strength. Twenty-one carriers had minimal muscle weakness
in hip flexion or shoulder abduction only (MRC 4+/5). Eight














































































Fig. 1 a-c: All clinical features scored by the NMDAS. Results of the
Newcastle Mitochondrial Disease Adult Scale (NMDAS) are shown
divided in the three sections of the scale, for all adult carriers of the
m.3243A > G mutaion (n071). a) Section 1: Current function; b)
Section 2: System-specific involvement; C) Section 3: Current clinical
assessment
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four carriers had moderate muscle weakness (MRC 4) with
difficulty to rise from 90 degree squat. One patient was
unable to rise from 90 degree squat.
Cardiomyopathy Twenty-five carriers (38.5%) had cardiac
involvement. Sixteen had asymptomatic changes on electro-
cardiogram, mainly repolarization disturbances. One had
asymptomatic left ventricular hypertrophy (LVH). Seven
had cardiomyopathy of which four had a ejection fraction
of less than 30%. One patient had a pacemaker for a com-
plete AV-block.
Epilepsy A history of seizures was present in nine carriers, of
which three had had seizures in the past year. Stroke-like epi-
sodes: a history of stroke-like episodes was present in four
carriers, of which three had Stroke-like Episodes in the past year.
Further neurologic examination Twelve carriers had subtle
sensory symptoms or areflexia (in knee and elbow reflexes).
Four carriers showed symptoms of pyramidal involvement and
two carriers showed symptoms of extrapyramidal involvement.
Section 4 of the NMDAS scores quality of life (QoL). It
distinguishes quality of physical health (QoLP) and quality
of mental health (QoLM). QoLP had a range of 17 to 61,
with a median of 41 (IQR 32-50). QoLM had a range of 25
to 66, with a median of 48 (IQR 42-48) (Fig. 2).
Using a t-test a significant (P<0.001) lowerQoLPwas found
in patients carrying the m.3243A > G mutation against the test
average of 50. No difference in QoLM in carriers against the test
average could be found (p00.055). Comparing quality of life in
carriers to non-carriers, there was a significant lower QoLP in
carriers (P<0.001) and no difference in QoLM (p00.395). The
QoLP was significantly negatively correlated to the NMDAS
(r0-0.565 p>0.001). There was no correlation between QoL
and the heteroplasmy in any of the samples.
Heteroplasmy levels
Heteroplasmy levels in leucocytes were determined in 126
individuals (one child refused the blood draw), in UEC in
121 individuals (insufficient material was received at the
laboratory in six individuals) and in buccal mucosa in all
127 individuals. Eighty-two individuals had a heteroplasmy
level of ≥5% in at least one of the samples. In the carriers,
the mean heteroplasmy in leucocytes was 22% (range 2-
65%), in UEC 48% (range 4-96%) and 35% (range 2-74%)
in buccal mucosa. Despite these differences between the
samples there were strong pair wise correlations between
the samples (r00.657-0.854 p<0.001 / see Figs. 3a-c). A
negative correlation between the level of heteroplasmy and
age was present in all samples , for leucocytes r0-0.678 (p<
0.001), for UEC r0-0.337 (p00.003), and for buccal mucosa
r0-0.432 (p<0.001) (see Figs. 4a-c).
The heteroplasmy level in UEC was below the detection
limit in one (1%) carrier that did have a detectablemutation load
in buccalmucosa and leucocytes. Heteroplasmy levels in buccal
mucosa were below the detection limit in seven (9%) carriers
that did have a detectable mutation load in UEC. Heteroplasmy
levels in leucocytes were below the detection limit in 12 (15%)
carriers that did have a detectable mutation load in UEC.
A correlation between clinical condition of the patient
and the level of heteroplasmy could not be made using the
NPMDS in children, because of the limited number of
pediatric carriers included in the study. In adults, there was
a correlation between the score on the NMDAS and the
heteroplasmy, in leucocytes r00.254 (p00.032), in UEC
r00.294 (p00.016), and in buccal mucosa r00.427 (p<
0.001) (See figs. 5a-c. Patients with a NMDAS of more than
20 (n025), have a better correlation between the clinical
scores and the heteroplasmy levels in leucocytes (r00.366
(p00.072)), and UEC (r00.530 (p00.008)).
Discussion
Dormant carrier
Following the results of this study, we propose to introduce a
new term in the mitochondrial genetic nomenclature: dormant
carrier. The term “dormant carrier” is used to indicate that a
patient that has a mitochondrial mutation, but has no obvious
clinical symptoms of the mutation (yet). We have chosen this














Fig. 2 Quality of life Section 4 of the NMDAS is a QoL test, divided
in QoLP and QoLM. All adult carriers of the m.3243A > G mutation are
shown (n071). The line at 50 shows the US average of the test. QoLP
is significantly lower than the US average
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new term because we experienced that the nomenclature in
mitochondrial inheritance has an overlap with nomenclature
in Mendelian inheritance, which causes confusion in provid-
ing patient information. In the Mendelian nomenclature, a
carrier is a patient that has a recessive mutation on one allele,
and is never going to be a patient. On the contrary, a dormant
carrier of a mitochondrial mutation may at some point become
symptomatic (awake), depending on heteroplasmy levels and
unknown other factors. In patient counseling and preventive
medicine this makes a big difference.
NMDAS and NPMDS
Since the Newcastle scores consists of subjective questions
regarding the personal opinion of the patient on daily func-
tioning (Section 1) and the interpretation of the findings at
physical examination (Section 3), all patients were scored
separately by two investigators.
Only ten patients aged under 18 were included in the study.
All ten children had no or only minor complaints. However,
we did include four families in which a child had died earlier
because of symptoms of the m.3243A > G mutation, so no
definite assumption can be made concerning the phenotype of
the m.3243A > G mutation in children based on this study.
The study does however show that children can be free of
symptoms even with a high level of heteroplasmy (up to 93%
in UEC). The adult patients with high levels of heteroplasmy
developed complaints in late infancy to early adolescence.
The younger children with high levels of heteroplasmy should
therefore be closely monitored to indentify early symptoms of
the clinical expression of the mutation at an early stage.
MELAS syndrome
The m.3243A > G mutation is most known for its relation
with MELAS syndrome. In this study only one patient had


















































































Fig. 3 a-c: Heteroplasmy levels in all patients carrying the m.3243A > G mutation (n082) in three different samples (leucocytes, UEC and buccal
mucosa) are correlated
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stroke-like episodes (SLE) in the past year and three other
patients had SLE in the past. Other neurologic symptoms as
seizures (n09) and encephalopathy (n04) also occurred
infrequent. Giving an indication that MELAS syndrome is
not the primary expression of the m.3243A > G mutation in
this cohort. This finding is in line with recent reports
(Manwaring et al. 2007) that the m.3243A > G mutation is
much more prevalent than previously thought. Patients pre-
senting with symptoms of MELAS syndrome are often
referred to a specialized center in which exploratory re-
search for mitochondrial mutation in performed. A patient
with the m.3243A > G mutation with a MELAS syndrome
phenotype is therefore unlikely to be missed.
Maternally inherited diabetes deafness (MIDD)
Forty-eight patients (67.6%) of this study had self reported
hearing loss. Thirty-seven patients (52.1%) have diabetes
mellitus. Only six of the 37 patients with diabetes mellitus
do not have hearing loss. Making a total of 31 patients in
this study that have diabetes deafness, giving an indication
that MIDD is a more frequent expression of the m.3243A > G
mutation than MELAS syndrome. The combination of diabe-
tes mellitus and hearing loss is however less a trigger to refer a
patient to a specialized center. So a mutation analysis is less
frequently performed.
Multiorgan involvement
Besides the typical symptoms of MELAS syndrome or
MIDD we observed high frequencies of other symptoms.
Cardiac involvement, gastro-intestinal symptoms and visual
disturbances are most frequent. Cardiac involvement has
previously been described (Fayssoil 2009; Lev et al. 2004;
Wortmann et al. 2007). In our cohort we found a large group
















































































Fig. 4 a-c: Heteroplasmy vs age heteroplasmy levels in all patients carrying the m.3243A > G mutation (n082) show a negative correlation to age
in leucocytes, UEC and buccal saliva
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but some severely affected patients as well. In the four
patients with an ejection fraction of less than 30% the
cardiac problems dominate the clinical picture. A large
number of patients in our cohort exhibits gastro-intestinal
problems. In most cases patients suffer from mild to mod-
erate constipation or symptoms of irritable bowel syndrome.
In five patients symptoms required admission or even sur-
gical intervention. Cases of chronic intestinal pseudo ob-
struction have previously been described in patients with the
m.3243A > G mutation (Bergamin et al. 2008; Verny et al.
2008). Twenty-six percent of the patients reported visual
disturbances and 42% of the patients did not have a vision
of 1.0 on a brief visual acuity test. Previous reports indicate
the presence of macular dystrophy in patients with the
m.3243A > G mutation (Massin et al. 1999; Michaelides
et al. 2008). Because of this multi-organ involvement of the
m.3243A > G mutation we recommend that all carriers of
the mutation are checked for early stages of these symptoms
by specialized physicians, including a consultation by a
cardiologist and a ophthalmologist, also when there is no
diabetes present.
Quality of life
We assessed quality of life in our cohort using the
SF12v2questionnaire. As visualized in Fig. 2, a lower
QoLP is negatively correlated to the NMDAS. Indicating,
as suspected, that when a patient has more symptoms of the
m.3243A > G mutation, a lower QoLP is reported. QQoLM
was not different from healthy controls nor from their rela-
tives that do not carry the mutation. Twenty patient did
report a history of depression or anxiety. This was however

















































































Fig. 5 a-c: Heteroplasmy vs NMDAS score Heteroplasmy levels in leucocytes, UEC and buccal saliva in all adult patients carrying the m.3243A >
G mutation (n071) show a correlation to the score on the NMDAS
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Different samples
As indicated in Fig. 5a-c we found a correlation between
NMDAS and heteroplasmy in all three samples, of which
buccal mucosa had the best correlation (r00.427, p<0.001
versus r00.254, p00.032 in leucocytes and r00.294 , p0
0.016 in UEC). When we selected for the most severely
affected patients (NMDAS>20) we found stronger correla-
tion for leucocytes (r00.366 , p00.072) and UEC (r00.530,
p00.008). Whittaker et al. (2009) was the first to describe a
correlation between heteroplasmy and symptoms. We con-
firm the good ability of UEC heteroplasmy predict clinical
outcome but add that this accounts most for the more se-
verely affected patients. In the general group of carriers of
the m.3243A > G mutation heteroplasmy in buccal saliva
has a better ability to predict clinical outcome.
Different studies have described a decrease in hetero-
plasmy with increasing age (Frederiksen et al. 2006; Ma et
al. 2010; Rahman et al. 2001). As demonstrated in Fig. 4a-c,
we also find a decreasing heteroplasmy in all samples. The
decrease in heteroplasmy with increasing age is much more
prominent in leucocytes (r0-0.705, p<0.001) than in the
other samples (UEC r0-0.374, p00.001, buccal mucosa
r0-0.460, p<0.001). However the decrease in heteroplasmy
level with age can only be confirmed after a prospective
follow-up study. We also found that heteroplasmy in UEC
has a 26 percent point higher value than heteroplasmy in
leucocytes and a 11 percent point higher value than hetero-
plasmy in buccal mucosa. The m.3243A > G mutation was
undetectable in leucocytes in 12 patients in which the mu-
tation was detected in UEC. Of these 12 patients the muta-
tion was also undetectable in buccal mucosa in seven
patients. There was one patient in which the m.3243A > G
mutation could not be detected in UEC, where it was
detected in leucocytes and buccal mucosa. However we
should take into account that we can never predict the values
of untested tissues such asmuscle, heart, kidney, liver or brain.
This means that UEC are the best non-invasively available
tissue to test if a patient is suspected of the m.3243A > G
mutation.
Conclusion
We conclude that the m.3243A > G mutation causes a wide
variety of signs and symptoms, MIDD being the most preva-
lent phenotypic expression. Of the three non-invasively avail-
able tissues for testing heteroplasmy, we advise to use UEC to
detect the mutation. Dormant carriers should be checked
regularly by a specialized physician to see whether the disease
has awakened and to be early in preventing and treating
symptoms.
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